Oral Administration of Chios Mastic Gum or Extracts in Mice: Quantification of Triterpenic Acids by Liquid Chromatography-Tandem Mass Spectrometry

Abstract

Chios mastic gum, the resin obtained as an exudate from the trunk and branches of Pistacia lentiscus L var. chia, is used extensively as a constituent of herbal drugs or functional foods. The oral absorption of its major constituents still remains unclear. In the context of identifying the features of mastic gum that are responsible for either therapeutic effects or effects of nutritional value, a methodology based on high-performance liquid chromatography (HPLC) coupled to tandem mass spectrometry (MS/MS) was developed and applied for the quantification of mastic gum triterpenic acids, 24Z-isomasticadienonic acid (IMNA), and 24Z-isomasticadienolic acid (IMLA) in mouse plasma. The specific compounds were selected based on their biological activity and potential against Helicobacter pylori. Concentrations were determined simultaneously in mouse plasma after oral administration of mastic gum or total mastic extract without polymer (TMEWP) in order to evaluate the role of the natural polymer, poly-β-myrcene, in the absorption process. Following TMEWP administration in mice, circulating IMNA and IMLA plasma levels were significantly higher (approximately 10-fold) in comparison to IMNA and IMLA plasma levels following total mastic gum administration (CMG), suggesting that the polymer plays a critical role in the absorption process. More specifically following TMEWP administration, Cmax plasma values were 3300 ± 859 ng/mL for IMNA and 163 ± 58 ng/mL for IMLA. In comparison, following CMG administration, Cmax plasma values were 329 ± 57 ng/mL for IMNA and 28 ± 8 ng/mL for IMLA.

The methodological approaches presented in this study, along with the findings, offer valuable information on the availability of bioactive components following ingestion of mastic and facilitate the uses of mastic either as an ingredient of functional foods or as a herbal drug.

Key words

Pistacia lentiscus var. chia - Anacardiaceae - mastic - isomasticadienonic acid - absorption - liquid chromatography-tandem mass spectrometry

References

• 1 Wellmann M. Pedanii Dioscuridis Anazarbei de materia medica libri quinque. Berlin: Weidmann; 1907: 1-255 http://stephanus.tlg.uci.edu/inst/browser?uid=&lang=eng&work=656001&rawescs=N&betalink=Y&filepos=O&outline=Y&GreekFont=Unicode&GreekinputFon=Beta&SpecialChars=render&maxhits=5&context=3 Dioscorides Pedanious, De materia medica. Book 1, Chapter 70, Section 1, Lines 1–11
• 2 Magiatis P, Melliou E, Skaltsounis A L, Chinou I B, Mitakou S. Chemical composition and antimicrobial activity of the essential oils of Pistacia lentiscus var. Chia.  Planta Med. 1999;  65 749-752
• 3 Tassou C C, Nychas G J E. Antimicrobial activity of the essential oil of mastic gum (Pistacia lentiscus var. chia) on gram positive and gram negative bacteria in broth and model food system.  Int Biodeter Biodegradation. 1995;  36 411-420
• 4 Al-Habbal M J, Al-Habbal Z, Huwez F U. A double-blind controlled clinical trial of mastic and placebo in the treatment of duodenal ulcer.  Clin Exp Pharmacol Physiol. 1984;  11 541-544
• 5 Paraschos S, Magiatis P, Mitakou S, Petraki K, Kalliaropoulos A, Maragkoudakis P, Mentis A, Sgouras D, Skaltsounis A L. In vitro and in vivo activities of Chios mastic gum extracts and constituents against Helicobacter pylori.  Antimicrob Agents Chemother. 2007;  51 551-559
• 6 Kaliora A C, Stathopoulou M G, Triantafillidis J K, Dedoussis G V, Andrikopoulos N K. Chios mastic treatment of patients with active Crohn's disease.  World J Gastroenterol. 2007;  13 748-753
• 7 Balan K V, Prince J, Han Z, Dimas K, Cladaras M, Wyche J H, Sitaras N M, Pantazis P. Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from Pistacia lentiscus L. var. chia.  Phytomedicine. 2007;  14 263-272
• 8 He M L, Yuan H Q, Jiang A L, Gong A Y, Chen W W, Zhang P J, Young C Y, Zhang J Y. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells.  Cancer. 2006;  106 2547-2555
• 9 He M L, Li A, Xu C S, Wang S L, Zhang M J, Gu H, Yang Y Q, Tao H H. Mechanisms of antiprostate cancer by gum mastic: NF-kappaB signal as target.  Acta Pharmacol Sin. 2007;  28 446-452
• 10 Paraschos S, Andreadou I, Iliodromitis E, Zoga A, Magiatis P, Mitaku S, Kaklamanis L, Skaltsounis A L, Kremastinos D. Antiatheromatic and hypolipidemic activity of Chios mastic gum in anesthetized rabbits.  Planta Med. 2008;  74 132
• 11 Loizou S, Paraschos S, Mitakou S, Chrousos G, Lekakis I, Moutsatsou P. Chios mastic gum extract and isolated phytosterol tirucallol exhibit anti-inflammatory activity in human aortic endothelial cells.  Exp Biol Med (Maywood). 2009;  234 553-561
• 12 Triantafyllou A, Chaviaras N, Sergentanis T N, Protopapa E, Tsaknis J. Chios mastic gum modulates serum biochemical parameters in a human population.  J Ethnopharmacol. 2007;  111 43-49
• 13 Dabos K J, Sfika E, Vlatta L J, Frantzi D, Amygdalos I G, Giannikopoulos G. Is Chios mastic gum effective in the treatment of functional dyspepsia? A prospective randomised double-blind placebo controlled trial.  J Ethnopharmacol. 2010;  127 205-209
• 14 Dabos K J, Sfika E, Vlatta L J, Giannikopoulos G. The effect of mastic gum on Helicobacter pylori: a randomized pilot study.  Phytomedicine. 2010;  17 296-299
• 15 Barton D H R, Seoane E. Triterpenoids. Part XXII. The constitution and stereochemistry of masticadienonic acid.  J Chem Soc. 1956;  189 4150-4157
• 16 Assimopoulou A N, Papageorgiou V P. GC-MS analysis of penta- and tetra-cyclic triterpenes from resins of Pistacia species. Part I. Pistacia lentiscus var. Chia.  Biomed Chromatogr. 2004;  19 1077-1079
• 17 Marner F J, Freyer A, Lex J. Triterpenoids from gum mastic, the resin of Pistacia lentiscus.  Phytochemistry. 1991;  30 3709-3712
• 18 Van den Berg K J, Van der Horst J, Boon J J, Sudmeijer O. cis-1,4-Poly-β-myrcene: the structure of the polymeric fraction of mastic resin (Pistacia lentiscus L.) elucidated.  Tetrahedron Lett. 1998;  39 2645-2648
• 19 Tamvakopoulos C, Dimas K, Sophianos Z D, Han Z, Wyche J H, Pantazis P. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin.  Clin Cancer Res. 2007;  13 1269-1277
• 20 Tamvakopoulos C, Sofianos Z D, Garbis S, Pantazis P. Analysis of in vitro metabolites of diferuloylmethane (curcumin) by liquid chromatography tandem mass spectrometry on a hybrid quadrupole linear ion trap system: newly identified metabolites.  Eur J Drug Metab Pharmacokinet. 2007;  32 51-57
• 21 Sofianos Z D, Katsila T, Kostomitsopoulos N, Balafas V, Matsoukas J, Tselios T, Tamvakopoulos C. Pharmacokinetics and in vitro metabolism of leuprolide in mice – mass spectrometry based evaluation of efficacy and toxicity.  J Mass Spectrom. 2008;  43 1381-1392
• 22 Gnoatto S C B, Dassonville-Klimpt A, Da Nascimento S, Gale'ra P, Boumediene K, Gosmann G, Sonnet P, Moslemi S. Evaluation of ursolic acid isolated from Ilex paraguariensis and derivatives on aromatase inhibition.  Eur J Med Chem. 2008;  43 1865-1877
• 23 Småstuen Haug L, Thomsen C, Becher G. A sensitive method for determination of a broad range of perfluorinated compounds in serum suitable for large-scale human biomonitoring.  J Chromatogr A. 2009;  1216 385-393
• 24 Fotinos S, Panaitescu L, Kletsas D, Platsinis H, Zervolea I, Skaltsounis A L, Mitakou S, Magiatis P. Use of mastic and its components for the control of microbial infections. US Patent WO03092712-11-13. 2003
• 25 Qiao J, Li A, Jin X, Wang J. Mastic alleviates allergic inflammation in asthmatic model mice by inhibiting recruitment of eosinophils.  Am J Respir Cell Mol Biol. advance online publication 2010;  DOI: 10.1165/rcmb.2010-0212OC
• 26 Huang X, Wang H, Yuan Z, Li A, He M, Al K, Zheng Q, Qin H. Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells.  Acta Pharmacol Sin. 2010;  31 741-745